Award
National Cancer Institute 3P50CA281701-03S1
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
Recipient
University of TX MD Anderson Cancer Center
Award Amount
$177,085.00
Ceiling
$177,085.00
Awarded
September 16, 2025
Identifier
3P50CA281701-03S1
NIH grant awarded to University of TX MD Anderson Cancer Center to study the SIK2 inhibitor GRN-300's effect on PARP inhibitor sensitivity and T-cell function in ovarian cancer.
Description
This project aims to investigate the efficacy of the SIK2 inhibitor GRN-300 in enhancing PARP inhibitor sensitivity and improving cytotoxic T-cell function in ovarian cancer.